United Press International - January 6, 2012
STONY BROOK, N.Y., Jan. 6 (UPI) -- U.S. Food and Drug
Administration approval of the use of an anti-retroviral drug
offers a new weapon to treat HIV infection in children,
Dr. Sharon Nachman, associate dean for research and professor of
pediatrics at Stony Brook University School of Medicine, was the
principal investigator of a national multi-center clinical trial
that studied the safety and efficacy of the drug raltegravir in
HIV-infected children and adolescents.
Raltegravir, approved for use in adults in 2007, is part of a
class of medications called HIV integrase inhibitors.
In the clinical trial all of the 96 patients enrolled had
previously been treated with a regimen of other HIV medications
before raltegravir. After being treated for 24 weeks with
raltegravir, 53 percent of the patients had an undetectable
amount of HIV in their blood.
"Raltegravir is an important new option for children with HIV.
The trial shows it has an excellent efficacy profile in children
with HIV who have failed other regimens and is also effective
against the virus regardless where the child lives around the
word," Nachman said in a statement. "The data also shows no
significant toxicities or interactions with other HIV
The formulation of raltegravir in children is a pill that can be
taken twice daily, with or without food.